<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The high expression of the T-cell oncogene TCL1 in B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and the emergence of B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> in TCL1-transgenic mice suggest a pathogenetic role for this kinase coregulator in B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We compared the expression of TCL1 in B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with their differentiation stage </plain></SENT>
<SENT sid="2" pm="."><plain>As with <z:mpath ids='MPATH_458'>normal</z:mpath> B-cell subsets, uniform TCL1 expression was characteristic of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> of pregerminal center derivation such as precursor B-cell lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (85%, 47/55) and mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (84%, 49/58), and was more variable in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (57%, 28/49) </plain></SENT>
<SENT sid="3" pm="."><plain>Large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was less frequently positive for TCL1 (36%, 18/50), especially among cases of the activated B-cell type </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> types of Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, splenic marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and post-germinal center-derived <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, including plasma cell <z:mp ids='MP_0009440'>myeloma</z:mp> and MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, were negative for TCL1, except for 1 case </plain></SENT>
<SENT sid="5" pm="."><plain>In nearly <z:hpo ids='HP_0000001'>all</z:hpo> TCL1-expressing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, as with <z:mpath ids='MPATH_458'>normal</z:mpath> B cells, variations in cellular TCL1 levels were related to the proliferation and microenvironmental factors </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:mpath ids='MPATH_458'>normal</z:mpath> B cells, cell lines and primary B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples, TCL1 downmodulation occurred after prolonged cytokine treatment and/or B-cell receptor stimulation </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast to mature T-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> where TCL1 expression is always indicative of an activating TCL1 gene translocation, TCL1 expression in B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> parallels its regulation in non-neoplastic B cells </plain></SENT>
<SENT sid="8" pm="."><plain>Therefore, TCL1 expression can be used diagnostically as an indicator of the differentiation stage of a given B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
</text></document>